Institute of Biophysics and Cell Engineering offers consumers services for the treatment of keratitis and corneal dystrophies with autologous limbal stem cells and mesemchial stem cells, including services using these methods for adult patients In accordance with the medical license under an outsourcing agreement and is looking for partners interested in a distribution service agreement.

The use of a biomedical cell product (BMCP) based on autologous limbal stem cells and mesenchymal stem cells increases the effectiveness of the treatment of inflammatory-dystrophic diseases of the cornea compared to surgical and pharmacological approaches.

The treatment uses registered BMCP "Mesenchymal stem cells" (TU BY 100217351.004-2014 amend. No. 1) and "Human corneal limbal epithelial stem cells" (TU BY 100217351.012-2020).

Developers: State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus", Educational Institution "Belarusian State Medical University".

Manufacturers: State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus", Healthcare Institution "3rd City Clinical Hospital named after E. V. Klumova".

Improved treatment results for keratitis, corneal ulcers, corneal dystrophies (H16.0, H18.5 and T86.5).

Scope - medicine, ophthalmology.

Product consumers - healthcare organizations providing medical care to patients in outpatient, inpatient and day hospital settings.

More information about paid services for the population can be found on the Institute's website here.

Information is posted in Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), , стр. 294-295. (in Russian)

Treatment of scars and age-related skin atrophy using dermal fibroblasts is performed only at the State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus".

Medical services associated with cell therapy are provided to patients of the Republic of Belarus and foreign citizens.

Stem cell therapy is highly effective. Thus, an improvement in visual acuity in patients with inflammatory-dystrophic diseases of the cornea, who were treated with perilimbal injections of autologous stem cells, was shown in 87.8%. Most of the patients had severe concomitant eye pathology (acquired and congenital glaucoma, eye contusions with dislocation of the lens into the vitreous body, chemical burns of the ocular surface, recurrent uveitis of unknown etiology, congenital aniridia). However, even in such severe cases, cell therapy made it possible to improve and preserve visual functions.

The developed treatment method showed good tolerability and safety for the patient. Side effects are rare and do not pose a health hazard. The method is environmentally safe.

The State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus" produces BMCP, with the help of which medical care is provided on a paid basis in the Health Institution "3rd City Clinical Hospital named after E.V. Klumov".

Instructions for use "Method of treating keratitis and corneal dystrophies with autologous limbal stem cells and mesenchymal cells of adipose tissue", reg. No. 175-1219 dated 12/26/2019. (in Russian)

State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus" is a leading scientific center in the field of biophysics.

Directions of fundamental and applied scientific research of the Institute.

In the field of medical biotechnology:
- genetic engineering - development of innovative biomedical cell products based on genetically modified cells;
- immunology and allergology - development of new methods of treatment and diagnosis of allergic diseases and immune dysfunctions;
- innovative vaccines - development of prototypes of domestic DNA and RNA vaccines for the prevention of viral diseases;
- new approaches to diagnostics - development of new technologies for early diagnosis of diseases and methods of personalized medicine aimed at improving the quality of human life;
- genome editing - somatic, induced pluripotent stem cells, which will allow treating diseases, including orphan, genetic;
- synthetic morphogenesis - including tissue and organ engineering.

In the field of bioinformatics technologies:
- structure-based design of new-generation drugs, development of innovative targeted antitumor and antiviral drugs using structural bioinformatics methods;
- synthesis of targeted drugs and their testing in vitro.

In the field of nanotheranostics and personalized nanomedicine:
- development of means of targeted delivery of new-generation therapeutic drugs using nanomaterials;
- development of biological nanochips for disease diagnostics;
- study of broad-spectrum biocompatible nanomaterials for the creation of biomedical cellular products, artificial organs, fundamentally new materials with antimicrobial, antiviral and anti-inflammatory activity.

Activities of the Center for Experimental and Applied Virology:
- culturing viruses, developing new methods for culturing human viruses to create diagnostic tools, medical prevention and treatment of viral diseases;
- creation of vaccine prototypes - against influenza (inactivated and recombinant), against African swine fever (vector), against pulmonary tuberculosis (therapeutic based on donor dendritic cells), innovative drugs against influenza.

Over the past years, the Institute has implemented a number of international contracts and agreements within the Framework Programs of the European Union, as well as with leading scientific centers, foundations, and societies.

Consumers interested in purchasing services for the treatment of keratitis and corneal dystrophies with autologous limbal stem cells and mesemmial stem cells, including services using these methods for adult patients in accordance with the medical license under an outsourcing agreement.

Partners interested in purchasing services for the treatment of keratitis and corneal dystrophies with autologous limbal stem cells and mesemmial stem cells, including services using these methods for adult patients in accordance with the medical license under a distribution services agreement.